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Background and Purpose: Rapid treatment of acute ischemic stroke (AIS) depends on 
sufficient staffing which differs between Stroke Centres and Stroke Units in Switzerland. We 
studied the effect of admission time on performance measures of AIS treatment and related 
temporal trends over time. 
Methods: We compared treatment rates, door-to-image-time, door-to-needle-time, and door-
to-groin-puncture-time in stroke patients admitted during office hours (Monday-Friday 8:00-
17:59) and non-office hours at all certified Stroke Centres and Stroke Units in Switzerland, as 
well as secular trends thereof between 2014 and 2019, using data from the Swiss Stroke 
Registry. Secondary outcomes were modified Rankin Scale and mortality at 3 months. 
Results: Treatment rates for IVT/EVT were higher during non-office hours compared with 
office hours in Stroke Centres (40.8 vs 36.5%) and Stroke Units (21.8 vs 18.5%). Door-to-
image-time and door-to-needle-time increased significantly during non-office hours. Door-to-
groin-puncture-time at Stroke Centres was longer during non-office hours compared to office 
hours (95 vs 84 minutes). Admission during non-office hours was independently associated 
with worse functional outcome and increased mortality. From 2014 to 2019, median door-to-
groin-puncture-time improved from 112 to 84 minutes and the treatment rate for wake-up 
strokes increased from 13 to 32%. 
Conclusions: Despite differences in staffing, patient admission during non-office hours 
delayed IVT to a similar, modest degree at Stroke Centres and Stroke Units. A larger delay of 
EVT was observed during non-office hours, but Stroke Centres sped up delivery of EVT over 
time. Patients admitted during non-office hours had worse functional outcomes, which was 

























   
   
   
   
   
   
   
   
   
   






Non-standard Abbreviations and Acronyms 
IVT: intravenous thrombolysis 
EVT: endovascular therapy 
sICH: symptomatic intracranial hemorrhage 
SSR: Swiss Stroke Registry 
CTU: Clinical Trial Unit 
DIT: door-to-image-time 
DNT: door-to-needle time 
DPT: door-to-groin-puncture time 
OH: office hours 

























   
   
   
   
   
   
   
   
   
   







Intravenous thrombolysis (IVT) and endovascular recanalization therapy (EVT) reduce 
disability in patients with acute ischemic stroke (AIS) (1,2). Rapid delivery of treatment is 
crucial and depends – among other factors – on the presence of experienced staff and access 
to infrastructure. In addition, acute stroke care has become more and more complex due to 
recent extension of time windows and imaging eligibility criteria in both IVT- and EVT-
treated patients (3,4). Furthermore, according to most stroke guidelines patients presenting 
with so called wake-up strokes can also benefit from acute reperfusion therapies depending on 
certain imaging features (5,6,7). These aspects represent a considerable challenge for staff 
involved in the acute treatment of AIS. 
However, staff levels and availability of infrastructure may vary depending on time of the day 
and day of the week, and differ between Stroke Centres and Stroke Units. In Switzerland, 
certification guidelines require a 24/7 attendance of a stroke neurologist at Stroke Centres 
whereas an on-call service is permitted at night and on weekends at Stroke Units following 
the guidelines of the European Stroke Organisation (8). Understanding the effect of day and 
time of admission on delivery and functional outcome of acute stroke care is relevant for 
service providers and health policy makers. 
Previous research on the effect of admission during “office-hours” versus “non-office hours” 
on the speed of delivery and outcomes of IVT was done in heterogeneous settings and yielded 
controversial results (9-13). Importantly, most of the previous research investigated patient 
cohorts when neither EVT per se, nor reperfusion treatment for AIS in the extended time 
window were widely implemented in everyday practice. The increasing proportion of stroke 
patients receiving EVT poses greater demands on staff and infrastructure. As of now, little is 
known on circadian and weekday variation of the speed of delivery and outcome of EVT.  
In order to consolidate and extend the evidence on diurnal and weekday variations of acute 

























   
   
   
   
   
   
   
   
   
   






therapeutic concepts, we conducted the present study using prospectively collected data from 
the Swiss Stroke Registry (SSR) between 01/2014 and 12/2019. 
 
Methods 
According to the AHA Journals’ implementation of the Transparency and Openness 
Promotion Guidelines, all data and materials can be accessed by request from the 
corresponding author (valerian.altersberger@usb.ch). 
 
Study design 
For this cohort study, we used prospectively collected data from the Swiss Stroke Registry 
(SSR). The SSR is a national web-based registry designed to facilitate multi-centric research 
in acute stroke and assure the provision and quality of acute stroke care in Switzerland, which 
started in January 2014 (14). The registry collects a standardized dataset of all patients with 
acute stroke, TIA and other acute cerebrovascular events including a follow-up assessment 
after 3 months. The registry is compulsory for all hospitals certified as Stroke Units or Stroke 
Centres in Switzerland, in line with the European Stroke Organisation criteria (15). The 
database is managed by the Clinical Trial Unit (CTU) of the University of Basel. Data 
collection is done locally in each Stroke Centre/ each Stroke Unit. All patients with ischemic 
stroke admitted between 01.01.2014 and 31.12.2019 were included. 
Parameters of interest for the present study were age, sex, National Institutes of Health Stroke 
Scale (NIHSS) score (16), date and time of stroke onset (or last seen well), of hospital 
admission, of first image and of treatment initiation (IVT and/or EVT), presence of wake up 
stroke, blood pressure prior to IVT treatment, glucose levels in blood serum on admission, 
vascular risk factors according to predefined criteria (17) and prior treatment with 
anticoagulation as well as pre-stroke functional status measured by the modified Rankin Scale 

























   
   
   
   
   
   
   
   
   
   






patient awoke but not prior to falling asleep. Clinical data, neurologic and functional 
outcomes during hospitalization and at 3 months after stroke were also collected. Clinical 
evaluations, as well as NIHSS and mRS assessments, were performed by certified stroke 
neurologists as part of their clinical activity. If an in-person visit was not possible at 3 months, 
mRS score was assessed by a phone interview with mRS-trained examiners.  
 
Outcomes 
Primary outcomes were the rate of patients with acute reperfusion therapy (i.e. the proportion 
of patients with AIS receiving IVT and/or EVT) and in-hospital performance measures in 
patients receiving IVT and/or EVT), defined as the following time intervals: (i) from hospital 
admission to brain imaging in IVT/EVT (“door-to-image-time” (DIT)) (ii) from hospital 
admission to start of IVT (“door-to-needle time” (DNT)) (iii) from hospital admission to start 
of EVT (“door-to-groin-puncture time” (DPT)). EVT is exclusively performed in Stroke 
Centres in Switzerland. As secondary outcomes, we investigated functional status defined by 
the mRS, as well as mortality at 3 months.  
 
Statistical analyses 
Statistical analyses were performed with R version 3.6.3 (R Core Team (2020). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/). The database is implemented in the commercial 
software secuTrial (interActive Systems GmbH, Germany) and is managed by the Clinical 
Trial Unit (CTU) of the University of Basel aided by the secuTrialR package (19). 
We investigated differences in primary and secondary outcomes between patients admitted 
during “office hours” (OH) (Monday-Friday 8:00-17:59) and patients admitted during “non-

























   
   
   
   
   
   
   
   
   
   






Stroke Centers and Stroke Units separately. Continuous data were summarized as median and 
interquartile range (IQR). We compared the rates of acute reperfusion therapy using Chi2-test 
and the performance measures using Wilcoxon test. Performance measures during OH and 
NH were additionally compared using a linear mixed model where the respective center was 
included as random effect. Performance measures were log-transformed to better meet the 
normality assumption. 
The association between admission time and functional outcome as well as mortality was 
estimated by calculating odds ratios (OR) with 95% confidence intervals (95% CI), using 
ordered logistic regression models and binary logistic regression, respectively. Analyses were 
done both unadjusted and adjusted for baseline NIHSS, age, pre-stroke mRS, and stroke-
onset-to-treatment time (for patients receiving acute reperfusion therapy). Patients with 
missing data on the mRS at 3 months were excluded. Furthermore, we evaluated the change 
over time from 2014 until 2019 regarding in-hospital performance measures (DIT, DNT, 
DPT) to investigate any learning curve effects in Stroke Units and Stroke Centres separately 
in descriptive analyses. Performance measures displayed as median and IQR were analysed 
each year beginning in 01/2014. Patients referred to hospital with symptoms of wake-up 
stroke as well as patients with in-hospital strokes were excluded from these analyses.   
As an exploratory analysis, we also investigated the rate of patients treated with IVT or EVT 
for wake-up strokes for each year. 
 
Role of the funding source/ Ethics 
No sponsor was involved in study design; in the collection, analysis, and interpretation of 
data; in the writing of the report; and in the decision to submit the paper for publication. 
The study complied with the Declaration of Helsinki. The study was classified as a Quality 

























   
   
   
   
   
   
   
   
   
   






waived. In accordance with national law, patients were informed about the use of their 
routinely collected data for research purposes. Patients who denied use of their data were 
excluded from the analysis. Anonymized data will be shared on request from any qualified 




Data were eligible for analysis in 31’788 (90.2%) of 35’261 AIS patients. Reasons for 
excluding patients were missing data on DIT, DNT or DPT (n = 3’473; 9.8%). 
 
Baseline characteristics  
11‘844 patients (48.7%) were admitted during office-hours (OH) and 12’471 (51.3%) during 
non-office hours (NH) in Stroke Centres. In Stroke Units, 3‘919 (52.4%) arrived during OH 
and 3‘554 (47.6%) during NH. Overall, there was no substantial difference in characteristics 
of AIS patients arriving during OH and those arriving during NH: age, sex, stroke severity, 
pre-stroke disability as well as the prevalence of cardiovascular risk factors were similar 
between groups. Stroke-onset-to-admission time was higher during OH in Stroke Centres and 
Stroke Units (Table 1). Among patients receiving acute reperfusion therapy, baseline 
characteristics were evenly distributed (Supplemental Table I).  
Patients in Stroke Centres had higher baseline stroke severity, were more likely to suffer from 
atrial fibrillation and more frequently under anticoagulation at the time of their stroke than 
patients treated in Stroke Units (Table 1).  
 

























   
   
   
   
   
   
   
   
   
   






Patients with AIS arriving during NH at Stroke Centres received acute reperfusion therapy 
with IVT or EVT more often than during OH (40.8% vs. 36.5%, p<0.001). Likewise, patients 
being admitted during NH to Stroke Units were more likely to be treated with IVT than 
during OH (NH 21.8% vs. OH 18.5%, p<0.001) (Table 2). 
Median DIT in patients treated with acute reperfusion therapy was faster during OH: Stroke 
Centres, DIT 23 vs 22 minutes, p<0.001; Stroke Units, DIT 19 vs 17 minutes; p<0.01. 
Fittingly, median DNT was significantly increased in patients arriving during NH compared 
to arriving during OH, both at Stroke Centres (43 vs 37 minutes, p<0.001) and Stroke Units 
(45 vs 39 minutes, p<0.001). Median DPT at Stroke Centres was longer in patients arriving 
during NH compared to OH (95 vs 84 minutes, p<0.001) (Table 2). 
The time differences between OH and NH for each primary outcome remained significant 
after calculating a linear mixed model with Stroke Centre or Stroke Unit included as random 
effect (Supplemental Table II). 
 
Secondary outcomes: Functional outcome and mortality 
After adjustment for age, baseline NIHSS and pre-stroke mRS, AIS patients arriving during 
NH in Stroke Centres had 1.11 (95% CI 1.04-1.18) times the odds of having a worse 
functional outcome at three months and OR 1.13 (95% CI 1.01-1.27) times the odds for 
mortality at 3 months compared with arriving during OH. Admission during NH in Stroke 
Units also increased the odds for worse functional outcome (1.12 (95% CI 0.99-1.26)) and 
mortality (1.15 (95% CI 0.89-1.49)) at 3 months without reaching statistical significance.  
Among patients receiving acute reperfusion therapy, admission during NH was again 
associated with worse outcome (1.18 (95% CI 1.07-1.31)) and mortality (1.18 (95% CI 1.01-
1.38)) at 3 months in Stroke Centres, after adjustment for patient characteristics and onset-to-

























   
   
   
   
   
   
   
   
   
   






worse outcome (1.12 (95% CI 0.87-1.46)) and mortality (1.48 (95% CI 0.89-2.47)) without 
reaching statistical significance (Table 3, Figure 1). 
 
Temporal trends in performance measures and treatment of wake-up strokes 
The median DIT for patients with acute reperfusion therapy remained relatively constant from 
2014 to 2019 at Stroke Centres and Stroke Units. Similarly, the median DNT remained 
relatively stable (Stroke Centre: 2014 39 vs 2019 40 minutes; Stroke Unit: 2014 38 vs 2019 
40 minutes). However, a considerable decrease of DPT at Stroke Centres (2014 112 vs 2019 
84 minutes) over time became apparent (Figure 2).  
The probability for acute reperfusion treatment of wake-up stroke with IVT and/ or EVT 
increased over time from 13.2% in 2014 to 25.0% in 2016, and to 31.7% in 2019 (Figure 3). 
 
Discussion 
Our study showed the following key results regarding the impact of day and time of 
admission on in-hospital p rformance measures and functional outcomes in ischemic stroke 
patients: (i) Despite differences in staffing, the speed of IVT was affected to a similar, modest 
degree by day and time of admission at Stroke Centres and Stroke Units. (ii) The initiation of 
EVT in Swiss Stroke Centres is delayed when being admitted during NH. (iii) Admission 
during NH is associated with worse outcome and increased mortality at 3 months independent 
of patient characteristics and delays in treatment delivery. (iv) Over time (2014-2019), the 
speed of delivery of EVT as well as the treatment rate for wake up strokes have increased.  
 
In our study population about 50% of all ischemic stroke patients were admitted during NH, 

























   
   
   
   
   
   
   
   
   
   






OH, both at Stroke Centres (40.8% vs 36.5%) and Stroke Units (21.8% vs 18.5%). We 
observed that AIS patients were admitted considerably faster during NH than during OH, 
which may have contributed to the higher reperfusion therapy rate.  
We found a statistically significant delay in delivery of IVT during NH, both at Stroke 
Centres and Stroke Units. Previous studies on diurnal variations of service provision in acute 
stroke treatment have yielded inconsistent results: A Swedish study found that DNT within 30 
minutes was less likely during NH (12). In line, Reuter et al. found the longest DNT time and 
the lowest IVT rate between 03:01 and 06:00 am (9). Furthermore, Kristiansen et al. found in-
hospital performance measures overall – but not thrombolysis rates – to be worse in patients 
admitted during NH (20). Other studies, however, showed no association of DNT with time of 
hospital arrival (11) and no deterioration of acute reperfusion therapy rates in candidates for 
thrombolytic therapy (21).  
Differences in staffing of emergency and radiology departments (independent of acute stroke 
services) might contribute to the higher DNT during NH by delaying image acquisition and 
decision-making (12). However, the delays in DIT in the present study during NH were very 
minor (median DIT: Stroke Centres: 23 vs 22 minutes; Stroke Units 19 vs 17 minutes). Some 
studies have also reported that patients admitted during NH may have more severe strokes and 
more comorbidities, potentially rendering treatment decisions more difficult (12,22). Yet in 
our study, baseline characteristics regarding comorbidities and stroke severity were well 
balanced between patients arriving during OH and NH. Another contributing factor to longer 
DNT during NH could be the experience of the treating physician and the availability of 
treating specialised stroke-neurologist. As there is little difference in DIT between NH and 
OH, the procedural step most sensitive to delay during NH appears to be the decision whether 
to administer IVT. In Stroke Units the treating physician is obliged to make contact with the 

























   
   
   
   
   
   
   
   
   
   






criteria in Switzerland require a 24/7 presence of a stroke neurologist. Despite these 
differences in staff requirements, the delay in DNT during NH compared with OH was similar 
at Stroke Centres (median 43 vs 37 minutes) and Stroke Units (45 vs 39 minutes), and only 
moderate in extent.  It has to be noted that patients admitted to Stroke Centres for IVT were 
more likely to take oral anticoagulation than patients treated at Stroke Units, which may cause 
additional delays in treatment during NH, depending on the availability of coagulation tests.  
Regarding the speed of EVT at Stroke Centres, we found a substantial, 11 minute in-house 
treatment delay during NH compared with admission during OH (median DPT 95 vs 84 
minutes). To date, only a few studies have investigated the impact of admission time on DPT: 
One study analysing data from 2013-2014 found longer door-to-reperfusion times for patients 
admitted during night-time and weekends in a small sample size (n=98) (23). Another study 
(n=189) reported significantly longer image-to-treatment times during NH (24). Recently, it 
was suggested that EVT in the morning is associated with good and EVT at the end of the 
workday with poor functional outcome (25). In the same study DPT was also increased during 
nighttime. Optimising EVT performance during NH is crucial because it has already been 
suggested that the majority of EVTs occur during NH, when transfer to hospital was reported 
to be delayed (24, 26). EVT is a staff-intensive procedure that requires presence of nurses, 
medical technical assistants, anaesthesiologists and neurointerventionalists. Furthermore, 
during NH the neurointerventionalist and other on-call staff have to travel to the hospital from 
home, in most settings (27). Overall, we observed a clear reduction in DPT over the years, 
indicating that Stroke Centres have continuously optimised their in-house procedures to 
deliver EVT (Figure 2). The same secular trend could not be observed for DNT, possibly 
indicating a certain ceiling effect in the way that IVT pathways were already optimised at the 
beginning of the capture period. However, counteracting trends prolonging DNT must also be 
considered, such as the increasing proportion of patients on oral anticoagulation receiving 

























   
   
   
   
   
   
   
   
   
   






and Stroke Units appear to have quickly adopted the recent evidence and treatment 
recommendations for wake-up stroke, indicated by a more than doubling in the proportion of 
patients with wake-up stroke receiving acute recanalization therapy from 2014 (13.41%) to 
2019 (31.7%) (Figure 3). 
Admission during NH resulted in higher odds for worse outcome and mortality in ischemic 
stroke patients similar to other studies investigating outcomes of patients suffering from AIS 
as well as other diseases during NH (12,13,29). This effect was not accounted for by 
differences in measured patient characteristics, rates of or delays in recanalization therapy. 
Factors such as the start of secondary prevention, availability of dysphagia screening, access 
to diagnostic tests and recognition of early complications may contribute to a true worsening 
in functional outcome when patients are admitted during NH. However, it is also possible that 
differences in unmeasured characteristics between patients admitted during NH and those 
admitted during OH may have caused residual confounding. E.g., diurnal variations in 
haemostasis, inflammation and cardiac biomarkers have been described (30).  
 
Strengths and Limitations 
One strength of the present study is the large sample size (n=35’261) with low number of 
missing data on primary outcomes (9.8%). Previous studies regarding EVT during NH were 
much smaller in comparison to the EVT sample size of the present study (n=4’183). 
Furthermore, data collection was performed from 01/2014 up to 12/2019 resulting in up-to-
date analyses reflecting the current situation of real world stroke service provision. Due to the 
timespan of 6 years we were able to investigate temporal trends such as learning curve effects 
after implementation of major modifications in acute stroke care. 
Our study has some limitations: Apart from general limitations of registry based, retrospective 

























   
   
   
   
   
   
   
   
   
   






NH and can only make assumptions. It is possible that unmeasured differences between OH 
and NH were missed in patients or settings, leading to residual confounding. Also, our results 




The delivery of acute recanalization therapy at Swiss Stroke Centres and Stroke Units is 
moderately delayed during non-office hours. Patients admitted during NH have a worse 
functional outcome which is not explained by availability or delay of recanalization therapy.   
Recent evidence and recommendations for treatment of wake-up stroke have been quickly 
adopted over the past few years. Overall, our findings show that Stroke Centres and Stroke 
Units certified in accordance to European guidelines are capable of providing round-the-clock 
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Figure 1: Modified Rankin Scale (mRS) at 3 months. A mRS at 3 months in all ischemic 
stroke patients. B mRS at 3 months in ischemic stroke patients treated with acute reperfusion 
therapy. 
Figure 2: Performance measures over time (years). 




























































 Stroke Center Stroke Unit 
 Office hours Non-office hours Office hours Non-office hours 
Patients, n(%) 11‘844 (48.7) 12’471 (51.3) 3‘919 (52.4) 3‘554 (47.6) 
Demographics     
Age, years, median[IQR] 75 [65-83] 75 [63-83] 76 [66-84] 75 [63-83] 
Male sex, n(%) 6739 (57.0) 7145 (57.4) 2170 (55.5) 2036 (57.3) 
Independent prior to stroke (pre-mRS 0-2), median[IQR] 9091 (88.1) 9745 (88.9) 2909 (89.3) 2657 (90.0) 
Stroke characteristics     
NIHSS, median[IQR] 4 [1-9] 4 [2-11] 3 [1-6] 3 [1-7] 
NIHSS, patients with acute reperfusion therapy, median[IQR] 9 [4-16] 9 [5-16] 6 [3-11] 6 [4-12] 
Onset-to-admission time, min,  median[IQR] 276 [86-982] 208 [81-645] 510 [108-1330] 238 [85-766] 
Medical history     
Hypertension, n(%) 8676 (74.7) 8996 (73.5) 2863 (76.9) 2560 (75.9) 
Diabetes mellitus, n(%) 2347 (20.2) 2495 (20.4) 802 (21.5) 752 (22.3) 
Coronary artery disease, n(%) 2040 (17.7) 2217 (18.2) 598 (16.8) 610 (18.8) 
Atrial fibrillation, n(%) 3031 (24.8) 2791 (24.0) 816 (22.0) 779 (23.2) 
Prior stroke, n(%) 2168 (18.7) 2274 (18.6) 657 (17.7) 617 (18.3) 
Systolic blood pressure, mmHg, median[IQR] 153 [137-172] 155 [138-175] 160 [140-180] 160 [141-180] 
Glucose, mmol/l, median[IQR] 6.3 [5.5-7.6] 6.5 [5.7-7.9] 6.3 [5.5-7.6] 6.5 [5.7-8.0] 
Medication     






























Table 2. Thrombolysis rate and performance measures. 
 
Office hours Non-office hours 
Office vs non-office hours, 
p-value 
Acute reperfusion therapy,  
n(%)a 
Stroke Center 4‘322 (36.5) 5’090 (40.8) <0.001 
Stroke Unit 724 (18.5) 773 (21.8) <0.001 
Door-to-image time, min, 
median(IQR)b 
Stroke Center 22 (16-30) 23 (17-31) <0.001 
Stroke Unit 17 (11-25) 19 (13-27) <0.01 
Door-to-IVT time, min,  
median(IQR) 
Stroke Center 37 (27-54) 43 (30-61) <0.001 
Stroke Unit 39 (29-53) 45 (32-65) <0.001 
Door-to-EVT time, min,  
median(IQR) 
Stroke Center 84 (59-116) 95 (66-130) <0.001 































Table 3. Multivariable analysis of outcomes. Odds ratio (95% confidence interval), p-value. 
  
Worse outcome Mortality 
All ischemic stroke patients1 Non-office hours vs office hours  
Stroke Center 1.11 (1.04-1.18)1 p=0.002 1.13 (1.01-1.27)1 p=0.036 
Stroke Unit 1.12 (0.99-1.26)1 p=0.078 1.15 (0.89-1.49)1 p=0.291 
Ischemic stroke patients with 
acute reperfusion therapy2 
Non-office hours vs office hours 
Stroke Center 1.18 (1.07-1.31)2 p<0.001 1.18 (1.01-1.38)2 p=0.034 
Stroke Unit 1.12 (0.87-1.46)2 p=0.374 1.48 (0.89-2.47)2 p=0.131 
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